NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

Core Insights - NewcelX Ltd. has appointed Dr. Julien Boisdron, a diabetes expert with over 20 years of experience in global diabetes care, to its Scientific Advisory Board [1][2][3] - Dr. Boisdron will provide strategic guidance for NewcelX's lead therapeutic program, IsletRx, which focuses on stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes [3][4] - The company emphasizes that Type 1 Diabetes is a primary clinical focus and a key priority in its development strategy [4] Company Overview - NewcelX Ltd. is a biotechnology company specializing in cell-based and small-molecule therapies for neurodegenerative and metabolic diseases [5] - The company combines advanced stem-cell technologies with neuroscience expertise to create scalable regenerative treatments targeting conditions like ALS and Type 1 Diabetes [5] - NewcelX is headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel [5]